What is the purpose of Ranibizumab 10mg injec?
Wet age-related macular degeneration is treated with Ranibizumab 10 mg injec (Lucentis) (AMD; an ongoing disease of the eye that causes loss of the ability to see straight ahead and may make Reading, driving, and other daily activities become more difficult).
How frequently is ranibizumab administered?
Patients must be evaluated on a frequent basis. Once a month, intravitreal injection of LUCENTIS 0.5 mg (0.05 mL of 10 mg/mL solution) is advised (approximately 28 days).
What is ranibizumab injection intravitreal?
The FDA originally approved intravitreal ranibizumab injection (LUCENTIS®; Genentech, Inc) in 2006 for wet age-related macular degeneration. It has now been approved for the treatment of diabetic macular edoema and macular edoema caused by a retinal vascular blockage.
What are the adverse effects of Ranibizumab 10mg injec?
- Side effects of ranibizumab
- Increased sensitivity to light; discharge or bleeding from the eye;
- seeing flashes of light or “floaters” in your vision; blurred vision, tunnel
- vision, eye pain, or seeing halos around lights; heightened sensitivity to
- light; ocular discharge or bleeding; visual flashes or “floaters”
For more details Click Here
We are an exporter from India and work in excess countries like the UAE, Oman, Qatar, Myanmar, Saudi Arabia, Netherlands, Albania, Saint Lucia, Jordan, Romania, South Africa
